Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

OBiO Completes Shanghai IPO for Gene/Cell CDMO Services; Trades 67% Higher

publication date: Mar 22, 2022

OBiO Technology, a Shanghai CDMO for gene and cell therapies, completed an IPO on the Shanghai STAR Exchange and traded 67% higher on its first trading day, an unusually strong performance in the current market. The company did not disclose how much the offering raised. Founded in 2013, OBiO is a contract research organization for vectorology and functional genomics studies. It also provides contract development and manufacturing services of IND-enabling CMC, along with clinical and commercial manufacturing. To date, the company has supported more than 100 gene and cell therapy programs More details....

Stock Symbol: (SHA: 688238)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.